DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 15.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,267 shares of the medical device company’s stock after selling 1,109 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in DexCom were worth $420,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in DXCM. Team Hewins LLC increased its holdings in DexCom by 3.4% in the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after buying an additional 83 shares in the last quarter. Bleakley Financial Group LLC raised its holdings in DexCom by 1.3% in the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after purchasing an additional 87 shares during the period. Capital Insight Partners LLC boosted its position in DexCom by 2.5% during the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after purchasing an additional 90 shares in the last quarter. HM Payson & Co. grew its holdings in DexCom by 6.0% in the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock valued at $247,000 after purchasing an additional 100 shares during the period. Finally, State of Alaska Department of Revenue increased its position in shares of DexCom by 0.3% in the first quarter. State of Alaska Department of Revenue now owns 41,830 shares of the medical device company’s stock valued at $5,801,000 after buying an additional 105 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Down 1.9 %

Shares of DXCM opened at $73.44 on Monday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The stock has a fifty day simple moving average of $70.11 and a two-hundred day simple moving average of $97.95. The company has a market capitalization of $29.21 billion, a PE ratio of 47.38, a price-to-earnings-growth ratio of 2.26 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. DexCom’s revenue was up 15.3% compared to the same quarter last year. During the same period last year, the business earned $0.34 earnings per share. As a group, equities analysts forecast that DexCom, Inc. will post 1.69 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DXCM. BTIG Research decreased their target price on DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Barclays decreased their price objective on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a report on Monday, July 29th. Oppenheimer cut their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday. Leerink Partners decreased their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Friday. Finally, UBS Group cut their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Six equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

Insider Activity

In other news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other DexCom news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at $4,607,617.95. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,824 shares of company stock valued at $126,390 in the last 90 days. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.